Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week Low – Here’s What Happened

Kailera Therapeutics, Inc. (NASDAQ:KLRA) hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $20.75 and last traded at $20.75, with a volume of 18105 shares trading hands. The stock had previously closed at $21.50.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on KLRA shares. Wall Street Zen raised shares of Kailera Therapeutics to a “hold” rating in a research note on Saturday, April 25th. Leerink Partners started coverage on shares of Kailera Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $36.00 target price on the stock. JPMorgan Chase & Co. started coverage on shares of Kailera Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $30.00 target price on the stock. Evercore started coverage on shares of Kailera Therapeutics in a research note on Tuesday. They issued an “outperform” rating on the stock. Finally, Jefferies Financial Group started coverage on shares of Kailera Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $48.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $42.75.

Kailera Therapeutics Trading Down 2.6%

Insider Activity at Kailera Therapeutics

In other news, Director Adam Koppel purchased 1,562,500 shares of the business’s stock in a transaction that occurred on Monday, April 20th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $25,000,000.00. Following the transaction, the director directly owned 22,583,268 shares of the company’s stock, valued at approximately $361,332,288. The trade was a 7.43% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Andrew T. Kaplan purchased 8,398,438 shares of the business’s stock in a transaction that occurred on Monday, April 20th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the transaction, the director directly owned 26,255,581 shares in the company, valued at $420,089,296. This trade represents a 47.03% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 10,460,938 shares of company stock worth $167,375,008 in the last ninety days.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.